A review of national guidelines for management of COPD in Europe

Marc Miravitlles, Claus Vogelmeier, Nicolas Roche, David Halpin, João Cardoso, Alexander G. Chuchalin, Hannu Kankaanranta, Thomas Sandström, Paweł ͆liwiński, Jaromir Zatloukal, Francesco Blasi

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.

Original languageEnglish
Pages (from-to)625-637
Number of pages13
JournalEuropean Respiratory Journal
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Chronic Obstructive Pulmonary Disease
Guidelines
Bronchodilator Agents
Russia
Therapeutics
Expectorants
Portugal
Quality of Health Care
Czech Republic
Wales
Poland
Finland
Theophylline
Disease Management
Sweden
England
Spain
Italy
France
Germany

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Miravitlles, M., Vogelmeier, C., Roche, N., Halpin, D., Cardoso, J., Chuchalin, A. G., ... Blasi, F. (2016). A review of national guidelines for management of COPD in Europe. European Respiratory Journal, 47(2), 625-637. https://doi.org/10.1183/13993003.01170-2015

A review of national guidelines for management of COPD in Europe. / Miravitlles, Marc; Vogelmeier, Claus; Roche, Nicolas; Halpin, David; Cardoso, João; Chuchalin, Alexander G.; Kankaanranta, Hannu; Sandström, Thomas; ͆liwiński, Paweł; Zatloukal, Jaromir; Blasi, Francesco.

In: European Respiratory Journal, Vol. 47, No. 2, 01.02.2016, p. 625-637.

Research output: Contribution to journalArticle

Miravitlles, M, Vogelmeier, C, Roche, N, Halpin, D, Cardoso, J, Chuchalin, AG, Kankaanranta, H, Sandström, T, ͆liwiński, P, Zatloukal, J & Blasi, F 2016, 'A review of national guidelines for management of COPD in Europe', European Respiratory Journal, vol. 47, no. 2, pp. 625-637. https://doi.org/10.1183/13993003.01170-2015
Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG et al. A review of national guidelines for management of COPD in Europe. European Respiratory Journal. 2016 Feb 1;47(2):625-637. https://doi.org/10.1183/13993003.01170-2015
Miravitlles, Marc ; Vogelmeier, Claus ; Roche, Nicolas ; Halpin, David ; Cardoso, João ; Chuchalin, Alexander G. ; Kankaanranta, Hannu ; Sandström, Thomas ; ͆liwiński, Paweł ; Zatloukal, Jaromir ; Blasi, Francesco. / A review of national guidelines for management of COPD in Europe. In: European Respiratory Journal. 2016 ; Vol. 47, No. 2. pp. 625-637.
@article{3fe1d51c1dff413fa9ba9ae481dc2223,
title = "A review of national guidelines for management of COPD in Europe",
abstract = "The quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.",
author = "Marc Miravitlles and Claus Vogelmeier and Nicolas Roche and David Halpin and Jo{\~a}o Cardoso and Chuchalin, {Alexander G.} and Hannu Kankaanranta and Thomas Sandstr{\"o}m and Paweł ͆liwiński and Jaromir Zatloukal and Francesco Blasi",
year = "2016",
month = "2",
day = "1",
doi = "10.1183/13993003.01170-2015",
language = "English",
volume = "47",
pages = "625--637",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - A review of national guidelines for management of COPD in Europe

AU - Miravitlles, Marc

AU - Vogelmeier, Claus

AU - Roche, Nicolas

AU - Halpin, David

AU - Cardoso, João

AU - Chuchalin, Alexander G.

AU - Kankaanranta, Hannu

AU - Sandström, Thomas

AU - ͆liwiński, Paweł

AU - Zatloukal, Jaromir

AU - Blasi, Francesco

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.

AB - The quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.

UR - http://www.scopus.com/inward/record.url?scp=84958078679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958078679&partnerID=8YFLogxK

U2 - 10.1183/13993003.01170-2015

DO - 10.1183/13993003.01170-2015

M3 - Article

VL - 47

SP - 625

EP - 637

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

ER -